Editorial: co-morbid gastrointestinal conditions are an important consideration in IBS management
- PMID: 33882166
- DOI: 10.1111/apt.16345
Editorial: co-morbid gastrointestinal conditions are an important consideration in IBS management
Comment in
-
Editorial: co-morbid gastrointestinal conditions are an important consideration in IBS management-authors' reply.Aliment Pharmacol Ther. 2021 May;53(10):1153-1154. doi: 10.1111/apt.16351. Aliment Pharmacol Ther. 2021. PMID: 33882164 No abstract available.
Comment on
-
Longitudinal follow-up of a novel classification system for irritable bowel syndrome: natural history and prognostic value.Aliment Pharmacol Ther. 2021 May;53(10):1126-1137. doi: 10.1111/apt.16322. Epub 2021 Mar 11. Aliment Pharmacol Ther. 2021. PMID: 33705578
References
REFERENCES
-
- Black CJ, Yiannakou Y, Guthrie E, et al. Longitudinal follow-up of a novel classification system for irritable bowel syndrome: natural history and prognostic value. Aliment Pharmacol Ther. 2021;53:1126-1137.
-
- Perera LP, Radigan M, Guilday C, et al. Presence of irritable bowel syndrome symptoms in quiescent inflammatory bowel disease is associated with high rate of anxiety and depression. Dig Dis Sci. 2019;64:1923-1928.
-
- Sainsbury A, Sanders DS, Ford AC. Prevalence of irritable bowel syndrome-type symptoms in patients with celiac disease: a meta-analysis. Clin Gastroenterol Hepatol. 2013;11:359-365.e1.
-
- Drossman DA. Functional gastrointestinal disorders: history, pathophysiology, clinical features, and Rome IV. Gastroenterology. 2016;150:1262-1279.e2.
-
- Hungin AP, Molloy-Bland M, Claes R, et al. Systematic review: the perceptions, diagnosis and management of irritable bowel syndrome in primary care-a Rome Foundation working team report. Aliment Pharmacol Ther. 2014;40:1133-1145.